Antigenic conservation of an immunodominant invariable region of the VlsE lipoprotein among European pathogenic genospecies of Borrelia burgdorferi SL

被引:69
作者
Liang, FT
Aberer, E
Cinco, M
Gern, L
Hu, CM
Lobet, YN
Ruscio, M
Voet, PE
Weynants, VE
Philipp, MT [1 ]
机构
[1] Tulane Univ, Med Ctr, Hlth Sci Ctr, Tulane Reg Primate Res Ctr,Dept Parasitol, Covington, LA 70433 USA
[2] Graz Univ, Dept Dermatol, Graz, Austria
[3] Univ Trieste, Dept Biomed Sci, Trieste, Italy
[4] Univ Neuchatel, Inst Zool, CH-2007 Neuchatel, Switzerland
[5] SmithKline Beecham Biol, Rixensart, Belgium
[6] Hosp Gemona, Dept Microbiol, Gemona, Italy
关键词
D O I
10.1086/315862
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Lyme disease is caused by genetically divergent spirochetes, including 3 pathogenic genospecies: Borrelia burgdorferi sensu stricto, B. garinii, and B. afzelii. Serodiagnosis is complicated by this genetic diversity. A synthetic peptide (C-6), based on the 26-mer invariable region (IR6) of the variable surface antigen of B. burgdorferi (VlsE), was used as ELISA antigen, to test serum samples collected from mice experimentally infected with the 3 genospecies and from European patients with Lyme disease, Regardless of the infecting strains, mice produced a strong antibody response to C-6, which indicates that IR6 is antigenically conserved among the pathogenic genospecies. Twenty of 23 patients with culture-confirmed erythema migrans had a detectable antibody response to C-6, A sensitivity of 95.2% was achieved, with serum samples collected from patients with well-defined acrodermatitis chronica atrophicans, Fourteen of 20 patients with symptoms of late Lyme disease also had a positive anti-IR6 ELISA, Thus, it is possible that C-6 may be used to serodiagnose Lyme disease universally.
引用
收藏
页码:1455 / 1462
页数:8
相关论文
共 43 条
[1]  
ACKERMANN R, 1984, YALE J BIOL MED, V57, P485
[2]   CHRONIC NEUROLOGIC MANIFESTATIONS OF ERYTHEMA MIGRANS BORRELIOSIS [J].
ACKERMANN, R ;
REHSEKUPPER, B ;
GOLLMER, E ;
SCHMIDT, R .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1988, 539 :16-23
[3]   EARLY AND LATE CUTANEOUS MANIFESTATIONS IN IXODES-BORNE BORRELIOSIS (ERYTHEMA MIGRANS BORRELIOSIS, LYME BORRELIOSIS) [J].
ASBRINK, E ;
HOVMARK, A .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1988, 539 :4-15
[4]   Interlaboratory comparison of test results for detection of Lyme disease by 516 participants in the Wisconsin State Laboratory of Hygiene College of American Pathologists proficiency testing program [J].
Bakken, LL ;
Callister, SM ;
Wand, PJ ;
Schell, RF .
JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (03) :537-543
[5]   A BORRELIA-SPECIFIC MONOCLONAL-ANTIBODY BINDS TO A FLAGELLAR EPITOPE [J].
BARBOUR, AG ;
HAYES, SF ;
HEILAND, RA ;
SCHRUMPF, ME ;
TESSIER, SL .
INFECTION AND IMMUNITY, 1986, 52 (02) :549-554
[6]   Analysis of antibody response to the outer surface protein family in Lyme borreliosis patients [J].
Batsford, S ;
Rust, C ;
Neubert, U .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (06) :1676-1683
[7]   AN EPIDEMIOLOGIC-STUDY OF LYME-DISEASE IN SOUTHERN SWEDEN [J].
BERGLUND, J ;
EITREM, R ;
ORNSTEIN, K ;
LINDBERG, A ;
RINGNER, A ;
ELMRUD, H ;
CARLSSON, M ;
RUNEHAGEN, A ;
SVANBORG, C ;
NORRBY, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (20) :1319-1324
[8]   Role of serology in the diagnosis of Lyme disease [J].
Brown, SL ;
Hansen, SL ;
Langone, JJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (01) :62-66
[9]  
*CDCP, 1997, MMWR-MORBID MORTAL W, V46, P531
[10]  
Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P590